Home/Filings/4/0000805928-24-000049
4//SEC Filing

DeVinney Erick Wayne 4

Accession 0000805928-24-000049

CIK 0000805928other

Filed

Mar 24, 8:00 PM ET

Accepted

Mar 25, 9:40 PM ET

Size

19.9 KB

Accession

0000805928-24-000049

Insider Transaction Report

Form 4
Period: 2024-03-16
DeVinney Erick Wayne
VP of Clin. & Trans. Sciences
Transactions
  • Sale

    Common Stock

    2024-03-21$7.68/sh716$5,499165,661 total
  • Sale

    Common Stock

    2024-03-21$7.68/sh3,141$24,123177,474 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-162,9502,950 total
    Common Stock (2,950 underlying)
  • Exercise/Conversion

    Common Stock

    2024-03-16+2,950168,611 total
  • Sale

    Common Stock

    2024-03-21$7.68/sh721$5,537167,890 total
  • Exercise/Conversion

    Common Stock

    2024-03-16+12,725180,615 total
  • Exercise/Conversion

    Common Stock

    2024-03-16+3,000166,377 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-163,0000 total
    Common Stock (3,000 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-1612,72512,725 total
    Common Stock (12,725 underlying)
Footnotes (6)
  • [F1]This reflects the number of restricted stock units that became vested as of March 16, 2024.
  • [F2]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
  • [F4]All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.
  • [F5]All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.
  • [F6]All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

Issuer

Axogen, Inc.

CIK 0000805928

Entity typeother

Related Parties

1
  • filerCIK 0001595972

Filing Metadata

Form type
4
Filed
Mar 24, 8:00 PM ET
Accepted
Mar 25, 9:40 PM ET
Size
19.9 KB